TY - JOUR
T1 - Molecular marker for predicting treatment response in advanced renal cell carcinoma
T2 - Does the promise fulfill clinical need?
AU - Garcia-Roig, Michael
AU - Ortiz, Nicolas
AU - Lokeshwar, Vinata
PY - 2014/1
Y1 - 2014/1
N2 - Renal cell carcinoma (RCC) is largely diagnosed incidentally on imaging taken for unrelated reasons. The management of localized lesions is primarily extirpative with excellent results. Treatment of advanced RCC has evolved over recent years with the use of targeted therapies such as tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, and antibody-mediated therapies. The treatment response to these targeted therapies is highly variable, with no clear clinical method of identifying patients who will benefit from or not tolerate therapy. The field of molecular markers has evolved significantly in the last decade, with a multitude ofmarkers identified that predict treatment response and drug toxicity. The following review critically evaluates those molecular markers that have been assessed for their utility in predicting treatment response in patients with advanced/metastatic renal cell carcinoma (mRCC). Identifying the ideal treatment for these patients will improve responses to therapy, minimize morbidity, and save significant healthcare dollars.
AB - Renal cell carcinoma (RCC) is largely diagnosed incidentally on imaging taken for unrelated reasons. The management of localized lesions is primarily extirpative with excellent results. Treatment of advanced RCC has evolved over recent years with the use of targeted therapies such as tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, and antibody-mediated therapies. The treatment response to these targeted therapies is highly variable, with no clear clinical method of identifying patients who will benefit from or not tolerate therapy. The field of molecular markers has evolved significantly in the last decade, with a multitude ofmarkers identified that predict treatment response and drug toxicity. The following review critically evaluates those molecular markers that have been assessed for their utility in predicting treatment response in patients with advanced/metastatic renal cell carcinoma (mRCC). Identifying the ideal treatment for these patients will improve responses to therapy, minimize morbidity, and save significant healthcare dollars.
KW - Metastatic renal cell carcinoma
KW - Prognostic markers
KW - Sorafenib
KW - Sunitinib
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=84893031630&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893031630&partnerID=8YFLogxK
U2 - 10.1007/s11934-013-0375-0
DO - 10.1007/s11934-013-0375-0
M3 - Article
C2 - 24337833
AN - SCOPUS:84893031630
SN - 1527-2737
VL - 15
JO - Current Urology Reports
JF - Current Urology Reports
IS - 1
M1 - 375
ER -